Navigation Links
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Date:11/8/2007

rointestinal bleeding (4%), dyspnea (3%), sepsis (1%), diarrhea (2%), congestive heart failure (2%), and pericardial effusion (1%).

Grade 3/4 elevations of transaminase or bilirubin and Grade 3/4 hypocalcemia and hypophosphatemia were reported in patients with all phases of CML, but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML and Ph+ ALL. Elevations in transaminase or bilirubin were usually managed with dose reduction or interruption. Patients developing Grade 3/4 hypocalcemia during the course of SPRYCEL therapy often had recovery with oral calcium supplementation.

Full Prescribing Information is available at http://www.SPRYCEL.com.

About Bristol-Myers Squibb

For more than 40 years, Bristol-Myers Squibb has been committed to building a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb's Research & Development organization are studying ways to improve current cancer treatments and identify better, more effective medicines for the future. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

For more information regarding SPRYCEL, please visit http://www.SPRYCEL.com

* Gleevec(R) is a registered trademark of Novartis AG


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... previously reported, communicated in late 2007 ... ... Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin alfa),following guidance from ... within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the label were based ...
... by the Environmental Protection Agency (EPA) to fine California ... nano-pesticides is being applauded by David Rejeski, the director ... should receive a big pat on the back for ... federal pesticide law that has been on the books ...
... FRANKLIN LAKES, N.J., March 7 BD (Becton,Dickinson and Company) ... that it would present at the following investor healthcare,conferences:, ... 13, 2008 8:45 a.m. Greenwich Mean Time (4:45 a.m. ... Company 28th Annual Healthcare Conference March 20, 2008 ...
Cached Biology Technology:Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7
(Date:7/9/2014)... climate change shifts the geographic ranges in which animals ... has on their parasites. Does an increased range for ... well? , Not necessarily, says a team of UC ... Kuris. In a study published in the Journal ... for some species, the opposite may happen: Hosts may ...
(Date:7/9/2014)... NY, July 9, 2014Biofuels derived from the oils produced ... fossil fuels. To achieve this goal, optimization of cost ... open pond systems, is needed. Sapphire Energy has developed ... open pond algae cultivation systems, described in Industrial ... Inc., publishers. The article is available on the ...
(Date:7/9/2014)... URBANA, Ill. With over 100 diseases that can ... the top of the most wanted list? University of ... reason that more research is needed on the fungus ... associated with cool, damp growing conditions but Macrophomina ... hot and dry drought conditions. , "As the climate ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... of how an abundance of fossils have been marvellously preserved ... of Africa has been solved by a team of geologists ... have established that an ancient wind brought life to the ... the dead. Sarah Gabbott, Jan Zalasiewicz and colleagues investigated ...
... a strategic alliance for catalysis research, "Munich Catalysis." In addition ... aspect of this cooperation will be the development of innovative ... global demand for energy and base chemicals on a long-term ... to two million euros a year. The cooperation is based ...
... The Great Tit is a common garden bird of many ... thought of as fairly inquisitive but it has long been ... surroundings. Some birds known as "fast" or "proactive" ... or "reactive" birds are more cautious. The differences are ...
Cached Biology News:Up to 20 million euros for Munich Catalysis research cooperation 2Up to 20 million euros for Munich Catalysis research cooperation 3Bird-brained? Birds' personalities are correlated with their hormone levels 2
...
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
...
Request Info...
Biology Products: